Robin K. Dore

2.2k total citations
33 papers, 1.6k citations indexed

About

Robin K. Dore is a scholar working on Rheumatology, Orthopedics and Sports Medicine and Oncology. According to data from OpenAlex, Robin K. Dore has authored 33 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Rheumatology, 13 papers in Orthopedics and Sports Medicine and 12 papers in Oncology. Recurrent topics in Robin K. Dore's work include Bone health and treatments (12 papers), Rheumatoid Arthritis Research and Therapies (12 papers) and Bone health and osteoporosis research (11 papers). Robin K. Dore is often cited by papers focused on Bone health and treatments (12 papers), Rheumatoid Arthritis Research and Therapies (12 papers) and Bone health and osteoporosis research (11 papers). Robin K. Dore collaborates with scholars based in United States, Netherlands and Canada. Robin K. Dore's co-authors include Lifen Zhou, Richard Newmark, Wayne Tsuji, Nancy E. Lane, Stanley Cohen, Charles Peterfy, P A Ory, John T. Sharp, Désirée van der Heijde and Paul D. Miller and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Journal of Bone and Mineral Research and Annals of the Rheumatic Diseases.

In The Last Decade

Robin K. Dore

33 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin K. Dore United States 14 727 662 639 511 318 33 1.6k
David W. Donley United States 14 1.4k 1.9× 1.1k 1.7× 895 1.4× 169 0.3× 511 1.6× 15 2.6k
D Ethgen Belgium 15 1.5k 2.1× 1.2k 1.8× 571 0.9× 507 1.0× 518 1.6× 32 2.2k
Blair Egerdie Canada 15 407 0.6× 916 1.4× 306 0.5× 229 0.4× 243 0.8× 31 1.7k
Matt Austin United States 9 2.0k 2.8× 1.8k 2.7× 1.3k 2.0× 224 0.4× 547 1.7× 17 2.9k
Cassandra E. Milmont United States 11 1.0k 1.4× 842 1.3× 852 1.3× 115 0.2× 210 0.7× 13 1.8k
Annette Schlemmer Denmark 13 463 0.6× 333 0.5× 258 0.4× 694 1.4× 61 0.2× 21 1.5k
S.H. Ralston United Kingdom 18 490 0.7× 350 0.5× 371 0.6× 105 0.2× 100 0.3× 35 1.0k
Joy N. Tsai United States 16 1.4k 1.9× 1.1k 1.6× 934 1.5× 77 0.2× 265 0.8× 27 1.8k
Aline G. Costa United States 17 467 0.6× 542 0.8× 459 0.7× 91 0.2× 411 1.3× 24 1.5k
Kalisha O’Neill United States 21 174 0.2× 167 0.3× 523 0.8× 451 0.9× 330 1.0× 35 2.6k

Countries citing papers authored by Robin K. Dore

Since Specialization
Citations

This map shows the geographic impact of Robin K. Dore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin K. Dore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin K. Dore more than expected).

Fields of papers citing papers by Robin K. Dore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin K. Dore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin K. Dore. The network helps show where Robin K. Dore may publish in the future.

Co-authorship network of co-authors of Robin K. Dore

This figure shows the co-authorship network connecting the top 25 collaborators of Robin K. Dore. A scholar is included among the top collaborators of Robin K. Dore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin K. Dore. Robin K. Dore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Swearingen, Christopher J., Theresa Lawrence Ford, Robin K. Dore, et al.. (2023). Associations of Cost Sharing With Rheumatoid Arthritis Disease Burden. ACR Open Rheumatology. 5(8). 381–387. 1 indexed citations
2.
Saag, Kenneth G., Michele McDermott, Jonathan D. Adachi, et al.. (2021). The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids. Arthritis & Rheumatology. 74(4). 604–611. 9 indexed citations
3.
Watts, Nelson B., Robin K. Dore, Sanford Baim, et al.. (2020). Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial. Osteoporosis International. 32(1). 55–61. 6 indexed citations
4.
5.
Bone, Henry G., Felicia Cosman, Paul D. Miller, et al.. (2018). ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 103(8). 2949–2957. 129 indexed citations
6.
Vollenhoven, Ronald van, Robin K. Dore, Heidi S. Camp, et al.. (2018). SAT0244 Impact of 12 weeks of upadacitinib treatment on individual and composite disease measures in patients with rheumatoid arthritis and inadequate response to conventional synthetic or biologic dmards. Annals of the Rheumatic Diseases. 77. 984–984. 1 indexed citations
7.
Dore, Robin K.. (2014). Clinical utility of etanercept in the treatment of arthritides in children and adolescents. Adolescent Health Medicine and Therapeutics. 5. 35–35. 3 indexed citations
8.
Dore, Robin K.. (2013). Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis. Patient Preference and Adherence. 7. 435–435. 9 indexed citations
9.
Dore, Robin K.. (2011). The RANKL Pathway and Denosumab. Rheumatic Disease Clinics of North America. 37(3). 433–452. 25 indexed citations
10.
Dore, Robin K.. (2011). Data from Extension Trials: Denosumab and Zoledronic Acid. Current Osteoporosis Reports. 10(1). 16–21. 4 indexed citations
11.
Deodhar, Atul, Robin K. Dore, David R. Mandel, et al.. (2010). Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care & Research. 62(4). 569–574. 96 indexed citations
12.
Dore, Robin K.. (2010). How to prevent glucocorticoid-induced osteoporosis. Cleveland Clinic Journal of Medicine. 77(8). 529–536. 26 indexed citations
13.
Dore, Robin K., Stanley Cohen, Nancy E. Lane, et al.. (2009). Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Annals of the Rheumatic Diseases. 69(5). 872–875. 138 indexed citations
14.
Dore, Robin K.. (2008). Gout. JCR Journal of Clinical Rheumatology. 14(5S). S47–S54. 9 indexed citations
15.
16.
Nevitt, Michael C., Douglas P. Kiel, J.-Y. Reginster, et al.. (2006). Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporosis International. 17(11). 1630–1637. 44 indexed citations
17.
Nevitt, Michael C., Peiqi Chen, Robin K. Dore, et al.. (2005). Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporosis International. 17(2). 273–280. 103 indexed citations
18.
Tesser, John, Roy Fleischmann, Robin K. Dore, et al.. (2004). Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.. PubMed. 31(4). 649–54. 29 indexed citations
19.
Fife, Rose, Robin K. Dore, Craig W. Wiesenhutter, et al.. (2002). Cevimeline for the Treatment of Xerostomia in Patients With Sjögren Syndrome. Archives of Internal Medicine. 162(11). 1293–1293. 142 indexed citations
20.
Dore, Robin K., et al.. (1995). Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study. Clinical Therapeutics. 17(4). 656–666. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David W. Donley Breakdown of academic impact, for papers by D Ethgen Breakdown of academic impact, for papers by Blair Egerdie Breakdown of academic impact, for papers by Matt Austin Breakdown of academic impact, for papers by Cassandra E. Milmont Breakdown of academic impact, for papers by Annette Schlemmer Breakdown of academic impact, for papers by S.H. Ralston Breakdown of academic impact, for papers by Joy N. Tsai Breakdown of academic impact, for papers by Aline G. Costa Breakdown of academic impact, for papers by Kalisha O’Neill
Rankless by CCL
2026